Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Accounts Payables (2016 - 2025)

IGC Pharma has reported Accounts Payables over the past 15 years, most recently at $628000.0 for Q3 2025.

  • Quarterly Accounts Payables fell 18.23% to $628000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $628000.0 through Sep 2025, down 18.23% year-over-year, with the annual reading at $883000.0 for FY2025, 14.23% up from the prior year.
  • Accounts Payables was $628000.0 for Q3 2025 at IGC Pharma, down from $933000.0 in the prior quarter.
  • Over five years, Accounts Payables peaked at $1.6 million in Q1 2021 and troughed at $357000.0 in Q4 2021.
  • The 5-year median for Accounts Payables is $773000.0 (2024), against an average of $857263.2.
  • Year-over-year, Accounts Payables tumbled 59.2% in 2021 and then surged 121.53% in 2022.
  • A 5-year view of Accounts Payables shows it stood at $357000.0 in 2021, then surged by 30.53% to $466000.0 in 2022, then soared by 39.06% to $648000.0 in 2023, then rose by 28.86% to $835000.0 in 2024, then decreased by 24.79% to $628000.0 in 2025.
  • Per Business Quant, the three most recent readings for IGC's Accounts Payables are $628000.0 (Q3 2025), $933000.0 (Q2 2025), and $883000.0 (Q1 2025).